MANKIND PHARMA Financial Statement Analysis
|
||
|
The Revenues of MANKIND PHARMA have decreased by -98.83% YoY .
The Earnings Per Share (EPS) of MANKIND PHARMA has increased by 1.05 % YoY. |
||
| REVENUES |
| OPERATING MARGIN |
| PROFIT AFTER TAX |
| EPS |
| ROCE |
MANKIND PHARMA Last 5 Annual Financial Results
[BOM: 543904|NSE : MANKIND]
| Consolidated | Mar2025 | Mar2024 | Mar2023 | Mar2022 | Mar2021 |
|---|---|---|---|---|---|
| Revenues | ₹10,260 Cr | ₹874,943 Cr | ₹7,782 Cr | ₹621 Cr | ₹58,719 Cr |
| Expenses | ₹7,745 Cr | ₹684,750 Cr | ₹5,791 Cr | ₹457 Cr | ₹44,272 Cr |
| Operating Profit (Excl OI) | ₹2,515 Cr | ₹190,193 Cr | ₹1,991 Cr | ₹165 Cr | ₹14,447 Cr |
| Other Income | ₹280 Cr | ₹12,857 Cr | ₹196 Cr | ₹17 Cr | ₹1,038 Cr |
| Interest | ₹34 Cr | ₹4,576 Cr | ₹60 Cr | ₹2.12 Cr | ₹232 Cr |
| Depreciation | ₹378 Cr | ₹32,592 Cr | ₹167 Cr | ₹12 Cr | ₹991 Cr |
| Profit Before Tax | ₹2,398 Cr | ₹167,124 Cr | ₹1,975 Cr | ₹169 Cr | ₹14,377 Cr |
| Profit After Tax | ₹1,941 Cr | ₹130,968 Cr | ₹1,453 Cr | ₹129 Cr | ₹10,561 Cr |
| Consolidated Net Profit | ₹1,913 Cr | ₹128,186 Cr | ₹1,433 Cr | ₹127 Cr | ₹10,304 Cr |
| Earnings Per Share (Rs) | ₹48.25 | ₹47.75 | ₹32.00 | ₹35.78 | ₹31.59 |
| PAT Margin (%) | 15.83 | 18.18 | 14.38 | 18.00 | 20.00 |
| ROE(%) | 16.98 | 23.14 | 19.27 | 26.72 | 31.51 |
| ROCE(%) | 18.32 | 28.35 | 23.49 | 33.96 | 39.97 |
| Total Debt/Equity(x) | 0.58 | 0.02 | 0.02 | 0.14 | 0.05 |
Key Financials |
||
| Market Cap | : | ₹ 92,956.4 Cr |
| Revenue (TTM) | : | ₹ 13,576.9 Cr |
| Net Profit(TTM) | : | ₹ 1,767.1 Cr |
| EPS (TTM) | : | ₹ 42.8 |
| P/E (TTM) | : | 52.6 |
| Industry Peers & Returns | 1W | 1M | 1Y |
| MANKIND PHARMA | 1.4% | -7.9% | -13% |
| SUN PHARMACEUTICAL INDUSTRIES | 2.8% | 6.7% | 2.8% |
| DIVIS LABORATORIES | 1.9% | -0.5% | 6.9% |
| CIPLA | 1.8% | -3.2% | 2.1% |
| TORRENT PHARMACEUTICALS | 0.1% | 3.4% | 15.8% |
| DR REDDYS LABORATORIES | 2.7% | 0.4% | 3.4% |
| ZYDUS LIFESCIENCES | 1.7% | -5.9% | -1.6% |
| LUPIN | 4.1% | 6.4% | 1.8% |
| AUROBINDO PHARMA | 2.5% | 10% | 0.6% |
MANKIND PHARMA Revenues
[BOM: 543904|NSE : MANKIND]
| Y-o-Y | -98.83 % |
| 5 Yr CAGR | -35.35 % |
| Years | Revenues | % Change | |
|---|---|---|---|
| Mar2025 | ₹10,260 Cr | -98.83 | |
| Mar2024 | ₹874,943 Cr | 11,143.81 | |
| Mar2023 | ₹7,782 Cr | 1,152.18 | |
| Mar2022 | ₹621 Cr | -98.94 | |
| Mar2021 | ₹58,719 Cr | - | |
MANKIND PHARMA Operating Profit
[BOM: 543904|NSE : MANKIND]
| Y-o-Y | -98.68 % |
| 5 Yr CAGR | -35.41 % |
| Years | Operating Profit | % Change | |
|---|---|---|---|
| Mar2025 | ₹2,515 Cr | -98.68 | |
| Mar2024 | ₹190,193 Cr | 9,454.83 | |
| Mar2023 | ₹1,991 Cr | 1,107.04 | |
| Mar2022 | ₹165 Cr | -98.86 | |
| Mar2021 | ₹14,447 Cr | - | |
| Operating Margins | |
|---|---|
| Y-o-Y | 12.74 % |
| 5 Yr CAGR | -0.09 % |
| Years | Operating Margin% | % Change | |
|---|---|---|---|
| Mar2025 | 24.51% | 12.74 | |
| Mar2024 | 21.74% | -15.01 | |
| Mar2023 | 25.58% | -3.62 | |
| Mar2022 | 26.54% | 7.89 | |
| Mar2021 | 24.6% | - | |
MANKIND PHARMA Profit After Tax
[BOM: 543904|NSE : MANKIND]
| Y-o-Y | -98.51 % |
| 5 Yr CAGR | -34.36 % |
| Years | Profit After Tax | % Change | |
|---|---|---|---|
| Mar2025 | ₹1,913 Cr | -98.51 | |
| Mar2024 | ₹128,186 Cr | 8,842.31 | |
| Mar2023 | ₹1,433 Cr | 1,032.80 | |
| Mar2022 | ₹127 Cr | -98.77 | |
| Mar2021 | ₹10,304 Cr | - | |
| PAT Margins | |
|---|---|
| Y-o-Y | -12.93 % |
| 5 Yr CAGR | -5.68 % |
| Years | PAT Margin(%) | % Change | |
|---|---|---|---|
| Mar2025 | 15.83 % | -12.93 | |
| Mar2024 | 18.18 % | 26.43 | |
| Mar2023 | 14.38 % | -20.11 | |
| Mar2022 | 18 % | -10.00 | |
| Mar2021 | 20 % | - | |
MANKIND PHARMA Earnings Per Share (EPS)
[BOM: 543904|NSE : MANKIND]
| Y-o-Y | 1.05 % |
| 5 Yr CAGR | 11.17 % |
| Years | EPS | % Change | |
|---|---|---|---|
| Mar2025 | ₹48 | 1.05 | |
| Mar2024 | ₹48 | 49.22 | |
| Mar2023 | ₹32 | -10.56 | |
| Mar2022 | ₹36 | 13.26 | |
| Mar2021 | ₹32 | - | |
MANKIND PHARMA Return on Capital Employed (ROCE)
[BOM: 543904|NSE : MANKIND]
| Y-o-Y | -35.38 % |
| 5 Yr CAGR | -17.72 % |
| Years | ROCE | % Change | |
|---|---|---|---|
| Mar2025 | 18.32% | -35.38 | |
| Mar2024 | 28.35% | 20.69 | |
| Mar2023 | 23.49% | -30.83 | |
| Mar2022 | 33.96% | -15.04 | |
| Mar2021 | 39.97% | - | |
MANKIND PHARMA Share Price vs Sensex
| Current Share Price | : | ₹2,251.9 |
| Current MarketCap | : | ₹ 92,956.4 Cr |
| Updated EOD on | : | Nov 28,2025 |
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| MANKIND PHARMA | 1.4% |
-7.9% |
-13% |
| SENSEX | 0.6% |
1.3% |
7% |
MANKIND PHARMA related INDICES
| BSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| BSE ALLCAP | 6.4% | 8.9% | 7.5% |
| BSE LARGEMIDCAP | 4.5% | 7.2% | 8.3% |
| BSE 500 SHARIAH | 4.3% | 4.3% | 1.1% |
| BSE HEALTHCARE | 1.1% | 0.2% | 3.5% |
| BSE 200 EQUAL WEIGHT | 0.7% | 0.5% | 5.7% |
| NSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| NIFTY PHARMA | 1.9% | 3.4% | 3.7% |
| NIFTY HEALTHCARE INDEX | 1.4% | 1.3% | 6.6% |
| NIFTY MIDCAP SELECT | 1.4% | 5.1% | 11.7% |
| NIFTY MIDCAP 50 | 1.3% | 2.9% | 11.7% |
| NIFTY MIDCAP 100 | 1.3% | 2.1% | 9.2% |
You may also like the below Video Courses
FAQ about MANKIND PHARMA Financials
How the annual revenues of MANKIND PHARMA have changed ?
The Revenues of MANKIND PHARMA have decreased by -98.83% YoY .
How the Earnings per Share (EPS) of MANKIND PHARMA have changed?
The Earnings Per Share (EPS) of MANKIND PHARMA has increased by 1.05 % YoY .
Check out Intrinsic Value of Peers of MANKIND PHARMA
Compare Stock Analytics of Peers of MANKIND PHARMA
SUN PHARMACEUTICAL INDUSTRIES LTD vs DIVIS LABORATORIES LTD vs CIPLA LTD
TORRENT PHARMACEUTICALS LTD vs DR REDDYS LABORATORIES LTD vs
SUN PHARMACEUTICAL INDUSTRIES LTD vs DIVIS LABORATORIES LTD vs CIPLA LTD
TORRENT PHARMACEUTICALS LTD vs DR REDDYS LABORATORIES LTD vs
